UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 376

Sortiert nach

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Frontiers in oncology, 2020-07, Vol.10, p.1000

2020

Volltextzugriff (PDF)

SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?

Journal of thoracic oncology, 2024-02, Vol.19 (2), p.193-195

Owonikoko, Taofeek K

2024

Volltextzugriff (PDF)

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Journal of clinical oncology, 2021-04, Vol.39 (12), p.1349-1359

2021

Volltextzugriff (PDF)

Lung cancer: New biological insights and recent therapeutic advances

CA: a cancer journal for clinicians, 2011-03, Vol.61 (2), p.91-112

2011

Volltextzugriff (PDF)

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

Cancer, 2018-01, Vol.124 (2), p.271-277

2018

Volltextzugriff (PDF)

The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer

Molecular cell, 2018-01, Vol.69 (1), p.87-99.e7

2018

Volltextzugriff (PDF)

Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer

Future oncology (London, England), 2021-03, Vol.17 (8), p.965-977

2021

Volltextzugriff (PDF)

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation

Clinical cancer research, 2017-11, Vol.23 (21), p.6567-6579

2017

Volltextzugriff (PDF)

Immune checkpoint inhibitors in small cell lung cancer

Journal of thoracic disease, 2018-02, Vol.10 (Suppl 3), p.S460-S467

2018

Volltextzugriff (PDF)

Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs

Cancer, 2015-10, Vol.121 (19), p.3390-3392

Owonikoko, Taofeek K.

2015

Volltextzugriff (PDF)

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

Journal of clinical oncology, 2018-08, Vol.36 (23), p.2386-2394

2018

Volltextzugriff (PDF)

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Journal of clinical oncology, 2023-06, Vol.41 (16), p.2893-2903

2023

Volltextzugriff (PDF)

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Cancer research (Chicago, Ill.), 2021-09, Vol.81 (18), p.4822-4834

2021

Volltextzugriff (PDF)

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

Journal of clinical oncology, 2019-01, Vol.37 (3), p.222-229

2019

Volltextzugriff (PDF)

The clinical conundrum of managing relapsed small cell lung cancer

Cancer, 2019-04, Vol.125 (7), p.1022-1026

2019

Volltextzugriff (PDF)

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

Cancer cell, 2018-08, Vol.34 (2), p.315-330.e7

2018

Volltextzugriff (PDF)

Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation

Oncogene, 2019-08, Vol.38 (35), p.6270-6282

2019

Volltextzugriff (PDF)

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

Journal of thoracic oncology, 2019-05, Vol.14 (5), p.876-889

2019

Volltextzugriff (PDF)

Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy

Cancer cell, 2015-06, Vol.27 (6), p.852-863

2015

Volltextzugriff (PDF)

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor–mutant lung cancers

Cancer, 2020-08, Vol.126 (16), p.3788-3799

2020

Volltextzugriff (PDF)

Systematic discovery of mutation-directed neo-protein-protein interactions in cancer

Cell, 2022-05, Vol.185 (11), p.1974-1985.e12

2022

Volltextzugriff (PDF)

Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion

Advances in therapy, 2021-11, Vol.38 (11), p.5431-5451

2021

Volltextzugriff (PDF)

Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth

Cancer cell, 2012-11, Vol.22 (5), p.585-600

2012

Volltextzugriff (PDF)

Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer

Molecular cancer therapeutics, 2013-10, Vol.12 (10), p.2200-2212

2013

Volltextzugriff (PDF)

The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo

PloS one, 2011-06, Vol.6 (6), p.e20899

2011

Volltextzugriff (PDF)

1 – 25 von 376

Suche als RSS-Feed

Aktive Filter

ThemaTumors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(355)
Mit Volltextzugriff
(368)

Publikationsform

Sprache

Englisch
(373)
Japanisch
(38)

Erscheinungsjahr

n.n

Thema

Science & Technology
(155)
Life Sciences & Biomedicine
(150)
Humans
(132)
Oncology
(128)
Female
(60)
Male
(59)
Lung Neoplasms - Drug Therapy
(47)
Lung Neoplasms - Pathology
(46)
Aged
(44)
Lung Cancer
(42)
Middle Aged
(42)
Cancer
(32)
Animals
(31)
Carcinoma, Non-Small-Cell Lung - Pathology
(31)
Adult
(28)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(26)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(26)
Cell Line, Tumor
(26)
Mice
(21)
Neoplasm Staging
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Lung cancer: New biological insights and recent therapeutic advances

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer

Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation

Immune checkpoint inhibitors in small cell lung cancer

Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

The clinical conundrum of managing relapsed small cell lung cancer

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor–mutant lung cancers

Systematic discovery of mutation-directed neo-protein-protein interactions in cancer

Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion

Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth

Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer

The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo

Aktive Filter

Suchergebnisse filtern